Maymetsi

Metformin Hydrochloride and Sitagliptin, the active ingredient in Maymetsi, is a Biguanide / DPP‑4 inhibitor presented as an oral tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults. GNH USA supplies Maymetsi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Maymetsi combines metformin and sitagliptin to improve glycaemic control in patients with type 2 diabetes mellitus. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels and improves overall glycaemic control.

Maymetsi may cause a range of adverse reactions.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhoea: loose stools, often transient. - Abdominal discomfort: cramping or pain. - Headache: mild tension‑type headaches. - Mild hypoglycaemia: especially when combined with other glucose‑lowering agents.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic disturbance. - Severe hypoglycaemia: marked low blood glucose requiring assistance. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Allergic reactions: rash, itching, or swelling. - Hepatic dysfunction: abnormal liver enzymes or liver injury.

Before initiating Maymetsi, several safety considerations should be reviewed. - Renal function monitoring: assess creatinine clearance to avoid accumulation. - Hepatic function assessment: evaluate liver enzymes for potential impairment. - Hypoglycaemia risk: educate patients on signs, especially when used with sulfonylureas. - Elderly patients: start at lower doses and monitor tolerance. - Concomitant medications: review for drugs affecting renal clearance or glucose metabolism. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Maymetsi can interact with various medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Severe renal impairment: contraindicates metformin use due to lactic acidosis risk. - Iodinated contrast agents: may precipitate acute kidney injury, requiring temporary discontinuation. - Alcohol abuse: increases risk of metformin‑associated lactic acidosis.

Moderate Interactions (Monitor Closely): - Sulfonylureas or insulin: may potentiate hypoglycaemia; dose adjustments may be needed. - Diuretics (e.g., thiazides): can affect renal function and electrolyte balance. - ACE inhibitors or ARBs: monitor renal function as combined effect may reduce clearance.